Palomar (NASDAQ:PLMR) Stock Rating Lowered by Wall Street Zen

Palomar (NASDAQ:PLMR) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Several other research analysts also recently commented on PLMR. Evercore assumed coverage on shares of Palomar in a report on Monday, February 9th. They issued an “outperform” rating and a $150.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Palomar from $155.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Weiss Ratings upgraded Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, January 14th. Finally, Keefe, Bruyette & Woods increased their target price on Palomar from $170.00 to $171.00 and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Palomar currently has a consensus rating of “Buy” and a consensus target price of $163.00.

Palomar Stock Performance

Shares of PLMR stock opened at $123.71 on Friday. The stock’s 50 day simple moving average is $128.55 and its 200 day simple moving average is $123.20. Palomar has a twelve month low of $107.75 and a twelve month high of $175.85. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of 17.23 and a beta of 0.44.

Palomar (NASDAQ:PLMR) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.06 by $0.18. Palomar had a return on equity of 22.77% and a net margin of 22.50%.The company had revenue of $253.36 million for the quarter, compared to the consensus estimate of $204.58 million. During the same quarter last year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 62.7% compared to the same quarter last year. On average, analysts forecast that Palomar will post 5.99 EPS for the current fiscal year.

Insider Activity

In related news, President Jon Christianson sold 1,991 shares of Palomar stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $119.88, for a total transaction of $238,681.08. Following the sale, the president directly owned 62,985 shares of the company’s stock, valued at $7,550,641.80. This trade represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO T Christopher Uchida sold 2,103 shares of the business’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $119.88, for a total value of $252,107.64. Following the transaction, the chief financial officer owned 11,473 shares in the company, valued at $1,375,383.24. This represents a 15.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 58,999 shares of company stock valued at $7,253,229. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in Palomar by 14.0% during the 3rd quarter. Principal Financial Group Inc. now owns 182,255 shares of the company’s stock worth $21,278,000 after purchasing an additional 22,346 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Palomar by 93.7% in the 2nd quarter. Osaic Holdings Inc. now owns 19,370 shares of the company’s stock valued at $2,933,000 after purchasing an additional 9,371 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Palomar during the 3rd quarter worth approximately $1,459,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Palomar by 11.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 456,172 shares of the company’s stock worth $53,258,000 after buying an additional 45,665 shares during the last quarter. Finally, Bessemer Group Inc. lifted its holdings in Palomar by 41.1% in the third quarter. Bessemer Group Inc. now owns 153,683 shares of the company’s stock valued at $17,943,000 after buying an additional 44,745 shares during the period. 90.25% of the stock is owned by institutional investors.

Key Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Zacks Research raised FY2026 EPS to $9.00 (from $8.00) and boosted FY2027 to $9.60 and FY2028 to $12.60 — a sizeable multi‑year upgrade that implies stronger forward profitability. MarketBeat PLMR
• Positive Sentiment: Zacks lifted several near‑term quarterly estimates: Q1 2026 to $2.07 (from $1.89), Q2 2026 to $1.95 (from $1.87), and Q3 2026 to $2.67 (from $1.91). They also raised Q1–Q3 2027 quarterlies (Q1 2027 to $2.46, Q2 2027 to $2.30, Q3 2027 to $2.82), reflecting a consistent upward revision pattern. MarketBeat PLMR
• Neutral Sentiment: A Zacks feature summarizing Street views notes the average analyst price target implies roughly 36.2% upside for PLMR — a bullish signal for sentiment but not a guarantee of price moves. Wall Street Analysts Think Palomar Could Surge
• Negative Sentiment: Zacks trimmed its Q4 2026 estimate slightly to $2.30 from $2.34 — a modest downgrade that appears isolated versus broad upward revisions elsewhere. MarketBeat PLMR

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.